Influence of genetic, biological and pharmacological factors on levodopa dose in Parkinson's disease

被引：31

作者：

Altmann, Vivian ^{[1
]}

Schumacher-Schuh, Artur F. ^{[2
]}

Rieck, Mariana ^{[1
]}

Callegari-Jacques, Sidia M. ^{[3
]}

Rieder, Carlos R. M. ^{[2
]}

Hutz, Mara H. ^{[1
]}

机构：

[1] Univ Fed Rio Grande do Sul, Inst Biociencias, Dept Genet, BR-90049 Porto Alegre, RS, Brazil

[2] Hosp Clin Porto Alegre, Serv Neurol, Porto Alegre, RS, Brazil

[3] Univ Fed Rio Grande do Sul, Dept Estat, Porto Alegre, RS, Brazil

来源：

PHARMACOGENOMICS | 2016年 / 17卷 / 05期

关键词：

algorithm; dopamine transporter; levodopa; Parkinson's disease; pharmacogenetics; synaptic vesicle isoform C; DOPAMINE TRANSPORTER GENE; SYNAPTIC VESICLE PROTEIN; BODY-WEIGHT; SV2C; PHARMACOKINETICS; LOCALIZATION; EXPRESSION; DYSKINESIA; BRAIN;

D O I：

10.2217/pgs.15.183

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Aim: Levodopa is first-line treatment of Parkinson's disease motor symptoms but, dose response is highly variable. Therefore, the aim of this study was to determine how much levodopa dose could be explained by biological, pharmacological and genetic factors. Patients & methods: A total of 224 Parkinson's disease patients were genotyped for SV2C and SLC6A3 polymorphisms by allelic discrimination assays. Comedication, demographic and clinical data were also assessed. Results: All variables with p < 0.20 were included in a multiple regression analysis for dose prediction. The final model explained 23% of dose variation (F = 11.54; p < 0.000001). Conclusion: Although a good prediction model was obtained, it still needs to be tested in an independent sample to be validated.

引用

页码：481 / 488

页数：8

共 50 条

[31] Mydriasis in a Parkinson's disease patient on low-dose carbidopa/levodopa
Burdick, D. J.
Griffith, A.
Cole, A.
Sia, C. M.
Agarwal, P.
MOVEMENT DISORDERS, 2013, 28 : S218 - S218
[32] Processing of Proprioceptive Information in Idiopathic Parkinson's Disease and the influence of Levodopa
Schrader, C.
Peschel, T.
Kossev, A. R.
KLINISCHE NEUROPHYSIOLOGIE, 2008, 39 (03) : 194 - 200
[33] Prosody and levodopa in Parkinson's disease
de Azevedo, Luciana Lemos
da Conceicao Reis, Cesar Augusto
de Souza, Irene Soares
Costa Cardoso, Francisco Eduardo
ARQUIVOS DE NEURO-PSIQUIATRIA, 2013, 71 (11) : 835 - 840
[34] Parkinson's disease - Levodopa complications
King, DB
CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES, 1999, 26 : S13 - S20
[35] Levodopa for Parkinson's Disease.
Devos, David
Moreau, Caroline
Destee, Alain
NEW ENGLAND JOURNAL OF MEDICINE, 2009, 360 (09): : 935 - 936
[36] Levodopa Fractionation in Parkinson's Disease
Nyholm, Dag
Stepien, Victoria
JOURNAL OF PARKINSONS DISEASE, 2014, 4 (01) : 89 - 96
[37] Levodopa in the treatment of Parkinson's disease
Schapira, A. H. V.
Emre, M.
Jenner, P.
Poewe, W.
EUROPEAN JOURNAL OF NEUROLOGY, 2009, 16 (09) : 982 - 989
[38] Levodopa, ayurveda and Parkinson's disease
Deleu, D
Hanssens, Y
Northway, MG
JOURNAL OF THE NEUROLOGICAL SCIENCES, 2001, 184 (01) : 89 - 90
[39] Levodopa in the treatment of Parkinson's disease
Koller, WC
NEUROLOGY, 2000, 55 (11) : S2 - S7
[40] Levodopa in the treatment of Parkinson's disease
Fahn, S.
JOURNAL OF NEURAL TRANSMISSION-SUPPLEMENT, 2006, (71): : 1 - 15

← 1 2 3 4 5 →